EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma

Abstract excerpt

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with few effective treatments. EGFR alterations, including expression of the truncated variant EGFRvIII, are among the most frequent genomic changes in these tumors. EGFRvIII is known to preferentially signal through STAT5 for oncogenic activation in GBM, yet targeting EGFRvIII has yielded limited clinical success to date. In this...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Cytokine Signaling Pathways and Interactions
• Share to Lung Cancer Treatments and Mutations